Bennet, Bindu, Pardo, Ingrid, Assaf, Basel, Buza, Elizabeth, Cramer, Sarah, Crawford, LaTasha, Engelhardt, Jefferey, Galbreath, Elizabeth, Grubor, Branka, Morrison, James, Osborne, Tanasa, Sharma, Alok and Bolon, Brad (2023) Scientific and Regulatory Policy Committee Technical Review: Biology and Pathology of Ganglia in Animal Species Used for Nonclinical Safety Testing. Toxicologic pathology, 51 (5). pp. 278-305. ISSN 1533-1601

Abstract

Dorsal root ganglia (DRG), trigeminal ganglia (TG), other sensory ganglia, and autonomic ganglia may be injured by some test article classes, including anti-neoplastic chemotherapeutics, adeno-associated virus-based gene therapies, antisense oligonucleotides, nerve growth factor inhibitors, and aminoglycoside antibiotics. This article reviews ganglion anatomy, cytology, and pathology (emphasizing sensory ganglia) among common nonclinical species used in assessing product safety for such test articles (TAs). Principal histopathologic findings associated with sensory ganglion injury include neuron degeneration, necrosis, and/or loss; increased satellite glial cell and/or Schwann cell numbers; and leukocyte infiltration and/or inflammation. Secondary nerve fiber degeneration and/or glial reactions may occur in nerves, dorsal spinal nerve roots, spinal cord (dorsal and occasionally lateral funiculi), and sometimes the brainstem. Ganglion findings related to TA administration may result from TA exposure and/or trauma related to direct TA delivery into the central nervous system or ganglia. In some cases, TA-related effects may need to be differentiated from a spectrum of artifactual and/or spontaneous background changes.

Item Type:	Article
Keywords:	Animals Ganglia, Spinal Nerve Fibers Spinal Cord Biology
Date Deposited:	12 Mar 2024 00:46
Last Modified:	12 Mar 2024 00:46
URI:	https://oak.novartis.com/id/eprint/50008